Illumina's technology suite, including the NovaSeqâ„¢ X Plus platform, 25B flow cell, and DRAGENâ„¢ analysis software, is designed to create an efficient end-to-end workflow for high-throughput ...
The combination of Illumina's Single Cell Prep, NovaSeqâ„¢ X Plus platform, 25B flow cell and DRAGENâ„¢ analysis software creates a seamless end-to-end workflow enabling the high-throughput ...
The integration of cutting-edge technologies is set to support the research community in undertaking billion-cell atlas studies, paving the way for new discoveries. Illumina's technology suite, ...
The combination of Illumina's Single Cell Prep, NovaSeq X Plus platform, 25B flow cell and DRAGEN analysis software creates a seamless end-to-end workflow enabling the high-throughput processing of ...
"Our new fiscal 2025 guidance provides for limited further earnings contribution from China, and assumes a continuation of the macro trends we see today," said Ankur Dhingra, CFO of Illumina. "We will ...
Longstanding partners bring together end-to-end workflows and leading CRISPR Perturb-seq technologies setting a standard for single-cell studies and enabling a 5 billion single-cell atlas ...
Illumina, Inc. ILMN recently entered into a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results